Amgen announced positive 52-week Phase 2 study results for MariTide (formerly AMG 133), a monthly or less frequently administered investigational treatment for obesity and overweight individuals. In participants without Type 2 diabetes, MariTide achieved up to ~20% average weight loss without plateauing, suggesting potential for further reductions. Those with Type 2 diabetes, who typically respond less to GLP-1 therapies, experienced up to ~17% weight loss and a 2.2-point reduction in HbA1C, also without a plateau.

MariTide improved cardiometabolic markers, such as blood pressure and triglycerides, with no impact on bone mineral density. Common side effects included mild and transient nausea and vomiting, primarily after initial doses. Dose escalation significantly reduced these effects.

Amgen is advancing to Phase 3 trials to evaluate MariTide’s weight loss potential further and explore durable effects post-treatment. The therapy is designed for convenient single-dose monthly injections and is part of Amgen’s broader obesity pipeline, which includes oral and injectable treatments with both incretin and non-incretin mechanisms.

MariTide's dual mechanism of GLP-1 receptor activation and GIPR antagonism offers a unique approach to managing obesity and Type 2 diabetes, with preclinical data supporting enhanced efficacy compared to targeting either pathway alone.